

Special Issue

Hippo Signaling in Cancer

Message from the Guest Editors

This Special Issue in *Cancers* aims to present the current achievements of scientific investigations focusing on Hippo signaling, with emphasis on oncogenesis, cancer progression, metastasis, cancer therapy resistance, and the development of targeted anticancer agents based on Hippo signaling. The topic is of particular importance because the dysregulation of Hippo signaling occurs in many types of human cancer and contributes to cancer development, progression, metastasis, and therapeutic resistance. Recent advances in methods and technologies of cell biology, molecular biology, immunology, and biochemistry have enabled fast growth in this area. This Special Issue aims to present the most important recent achievements in this unique field of cancer research.

Prof. Dr. Michel Ouellette

Guest Editors

Dr. Ying Yan

Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE 68198, USA

Prof. Dr. Michel Ouellette

1. Department Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA

2. Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA

Deadline for manuscript submissions

closed (20 February 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/147424

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)